Jolly, Jasleen K.

Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR

Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine

Retinal Development and DisordersVirus-based gene therapy research

Cited by 368

Visual Acuity after Retinal Gene Therapy for Choroideremia

Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine

Retinal Development and DisordersVirus-based gene therapy research

Cited by 195

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia

Xue, K., Jolly, J. K., Barnard, A. R., Rudenko, A., Salvetti, A. P., Patrício, M. I., Edwards, T. L., Groppe, M., Orlans, H. O., Tolmachova, T., et al. (2018) · Nature Medicine

Retinal Development and DisordersVirus-based gene therapy research

Cited by 185

Assessment of visual function with cotoretigene toliparvovec in X-linked retinitis pigmentosa in the randomized XIRIUS phase 2/3 study

Lam, B. L., Pennesi, M. E., Kay, C. N., Panda, S., Gow, J. A., Zhao, G., MacLaren, R. E., MacLaren, R., Aleman, T., Birch, D., et al. (2024) · Ophthalmology

Retinal Development and DisordersVirus-based gene therapy research

Cited by 51